AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2870943
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human insulin
Trial: 30403574
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg subcutaneously every 2 weeks)
Trial: 26981608
Drug: Comprehensive oral
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive oral health care (oral health examination, oral health education, topical fluoride application, dental treatment)
Trial: 26981608
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral health examination only)
Trial: 20580423
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) daily until delivery
Trial: 18648200
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) treatment, mean dose 158 mg, duration at least 3 months
Trial: 18648200
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) treatment
Trial: 11005755
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lidocaine
Trial: 1832607
Drug: Picotamide monohydrate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide monohydrate, 1200 mg daily three days before surgery, tapering to 900 mg daily postoperatively
Trial: 30249195
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (300 mg)
Trial: 27259709
Drug: EP217609 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP217609 (1, 3, or 10 mg)
Trial: 16392983
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy
Trial: 1975780
Drug: Nisoldipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (2 X 10 mg)
Trial: 1975780
Drug: Captopril (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (3 X 25 mg)
Trial: 27984226
Drug: Lidocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (20 mL 2% lidocaine with epinephrine)
Trial: 21273491
Drug: Insulin requirements
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin requirements during high altitude trekking
Trial: 21273491
Drug: Insulin doses
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin doses at altitudes >5,000 m
Trial: 19190034
Drug: Brief supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief supportive therapy
Trial: 17080587
Drug: Transdermal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal continuous hormone replacement therapy (HRT) with estradiol 50 microg/day and norethisterone acetate 140 microg/day (Estalis)
Trial: 17080587
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement therapy (HRT) with estradiol 2 mg and norethisterone acetate 1 mg (Kliogest)
Trial: 14769753
Drug: Nebulized opioids
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized opioids (morphine, hydromorphone)
Trial: 11443567
Drug: Endotoxin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin and ibuprofen
Trial: 11443567
Drug: Soluble tumor
RxNorm normalized name: SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-METHOXYPOLY(OXY-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble tumor necrosis factor receptor
Trial: 11443567
Drug: Soluble interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble interleukin-1 receptor
Trial: 2958817
Drug: Depilatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depilatory agent (group II)
Trial: 29669668
Drug: MF-sponsor (mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-sponsor (mometasone 50 μg)
Trial: 29669668
Drug: MF (mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF (mometasone 50 μg)
Trial: 26198280
Drug: 20 G
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 G vitrectomy and circumferential scleral buckling (E1)
Trial: 26198280
Drug: 20 G
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 G vitrectomy alone (C)
Trial: 26198280
Drug: 23/25 G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23/25 G vitrectomy alone (E2)
Trial: 22509949
Drug: Tiotropium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium treatment
Trial: 21120304
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (5 joule/cm² at each point over maximum 5‐6 painful points for 1 minute)
Trial: 18341614
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + Interferon (IFN)-beta
Trial: 16449522
Drug: 6-methylprednisolone (6MPred)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-methylprednisolone (6MPred) 2 mg/kg per day for 5 consecutive days
Trial: 16449522
Drug: 6MPred 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MPred 5 mg/kg per day for 10 days
Trial: 16449522
Drug: 6MPred 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MPred 5 mg/kg per day for 10 days + rabbit anti-thymocyte globulin (ATG, 6.25 mg/kg in 10 days)
Trial: 15804077
Drug: Sub-conjunctiva injection
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-conjunctiva injection of dexamethasone combined with eye drops of 1% CsA and 0.1% dexamethasone
Trial: 9823729
Drug: 0.5% KTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% KTP gel
Trial: 9823729
Drug: 1.0% KTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% KTP gel
Trial: 9823729
Drug: 1.0% KTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% KTP alternate gel
Trial: 9823729
Drug: 2.0% KTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% KTP gel
Trial: 9823729
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg KTP capsule (positive control)
Trial: 8911891
Drug: Human chorionic
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropin (twice‐weekly intramuscular injections for 5 weeks; total dose 2500 IU for patients less than 1‐year‐old, 5000 IU for 1‐ to 6‐year‐olds, 10000 IU for 6‐ to 11‐year‐olds)
Trial: 1529280
Drug: Cisapride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 10 mg three times daily for 14 days
Trial: 6732212
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg once a day for 5 days)
Trial: 6732212
Drug: Bacitracin ointment
RxNorm normalized name: Bacitracin Ointment
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bacitracin ointment (topically applied three times a day for 10 days)
Trial: 29764875
Drug: High-dose GHX02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GHX02 (1920 mg/day)
Trial: 29764875
Drug: Standard-dose GHX02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose GHX02 (960 mg/day)
Trial: 30925824
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran supplement containing PRB (43 μg LRA/day)
Trial: 23059159
Drug: BL-1020 20-30
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-1020 20-30 mg/d
Trial: 23059159
Drug: Risperidone (2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2-8 mg/d)
Trial: 23059159
Drug: BL-1020 10
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-1020 10 mg/d
Trial: 16055579
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.125% bupivacaine with 2 microg/mL fentanyl at a rate of 8 mL/h (group A)
Trial: 16055579
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus of 10 mL of 0.25% bupivacaine on demand (group B)
Trial: 1833042
Drug: Cisplatin, high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, high-dose cytosine arabinoside, and caffeine (CAC)
Trial: 6120313
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral immunisation with cholera B subunit
Trial: 6120313
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular immunisation with cholera B subunit
Trial: 6120313
Drug: Second immunisation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second immunisation by either route (oral or intramuscular)
Trial: 30638065
Drug: CBT-plus-fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-plus-fluoxetine
Trial: 26804640
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 25 mg of cinacalcet
Trial: 26804640
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 50 mg of cinacalcet
Trial: 26804640
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 100 mg of cinacalcet
Trial: 26804640
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 50 mg of cinacalcet once daily for 7 days
Trial: 26804640
Drug: Cinacalcet administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet administration (single and multiple doses)
Trial: 22353201
Drug: S-1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 at 25 mg twice daily for 5 days (level 1)
Trial: 22353201
Drug: S-1 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 at 40 mg twice daily for 5 days (level 2)
Trial: 17393237
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide and formoterol
Trial: 3289861
Drug: Topical hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hyperbaric oxygen (THO) treatment for 2 weeks
Trial: 3289861
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no THO treatment)
Trial: 26244877
Drug: ADT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT plus docetaxel (75 mg/m² every 3 weeks for six cycles)
Trial: 24195207
Drug: Acupuncture +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture + medication (SSRIs)
Trial: 24195207
Drug: Medication (SSRIs)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (SSRIs)
Trial: 19321522
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (participated in two weeks of daily training on weekdays)
Trial: 10516943
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indinavir sulfate 400 mg orally every 6 hours with placebo
Trial: 10516943
Drug: TMP 160
RxNorm normalized name: SMX 800 MG / TMP 160 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP 160 mg/SMZ 800 mg orally every 12 hours with placebo
Trial: 7586112
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 mg.kg‐1 (SxCh)
Trial: 7586112
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg.kg‐1 (Vec 0.3)
Trial: 7586112
Drug: Vecuronium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.5 mg.kg‐1 (Vec 0.5)
Trial: 7586112
Drug: Vecuronium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.5 mg.kg‐1 (Vec 0.5) in beta blocker group
Trial: 2149512
Drug: Isradipine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5-10 mg bid)
Trial: 2149512
Drug: Prazosin (2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2-8 mg bid)
Trial: 30280946
Drug: CE/BZA doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE/BZA doses and Placebo
Trial: 25138548
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers in induced sputum (MMP-9 and TIMP-1)
Trial: 22743565
Drug: Erythropoietin analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin analog treatment
Trial: 8596815
Drug: ProSol PDS
RxNorm normalized name: Prosol
DrugBank: Proline (DB00172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ProSol PDS 22‐4 (irrigating solution)
Trial: 26499250
Drug: tDCS‐control cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS‐control cognitive training (DCS‐CC)
Trial: 23255145
Drug: Topical perfluorodecalin
RxNorm normalized name: Perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical perfluorodecalin (PFD) with R0 method (3 passes)
Trial: 21254315
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (4 weeks)
Trial: 19497597
Drug: ExCHO -
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ExCHO - 80-minute resistance exercise bout while consuming CHO (approximately 77 g CHO, 306 kcal)
Trial: 11695214
Drug: Colgate Winterfresh
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Winterfresh Gel Fluoride Toothpaste
Trial: 9585725
Drug: Tomoxetine (76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomoxetine (76 mg/day)
Trial: 791107
Drug: Doxycycline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (2 mg/kg at the beginning, at 12 h, and once daily)
Trial: 791107
Drug: Tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride (administered at 6-h intervals)
Trial: 28349044
Drug: VPZ-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPZ-based treatment (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)
Trial: 28349044
Drug: PPI-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based treatment (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)
Trial: 28349044
Drug: VPZ-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPZ-based treatment
Trial: 28349044
Drug: PPI-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based treatment
Trial: 18053998
Drug: Synthetic conjugated
RxNorm normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic conjugated estrogens B (0.3 mg/d)
Trial: 17212913
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (medications, physical therapy, epidural steroid injections)
Trial: 11349266
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF), 1 g twice daily intravenously followed by 1.5 g twice daily orally
Trial: 11349266
Drug: Azathioprine (AZA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (AZA), 1.0 to 2.0 mg/kg/d intravenously followed by oral administration
Trial: 3435159
Drug: Human normal
RxNorm normalized name: Human normal immunoglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human normal immunoglobulin (50 mg/kg) administered weekly via intramuscular injection
Trial: 25558162
Drug: Varunadi Ghritha,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varunadi Ghritha, 5gms twice daily for one year
Trial: 18538051
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg kg(‐1) loading dose followed by 0.2 microg kg(‐1) h(‐1))
Trial: 18538051
Drug: Midazolam/Fentanyl (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam/Fentanyl (0.05 mg kg(‐1) midazolam and 1 microg kg(‐1) fentanyl)
Trial: 27507005
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (0.75 g/kg body weight)
Trial: 27507005
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein drink (0.75 g/kg body weight)
Trial: 18341431
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost (LA) administered once-daily for 3 months after switching from beta-blockers
Trial: 18341431
Drug: Topical beta-blockers
RxNorm normalized name: Beta-HC Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beta-blockers (carteolol hydrochloride, nipradilol, betaxolol hydrochloride) administered twice-daily for 3 months before switching to LA
Trial: 12432966
Drug: Extended-release Adderall
RxNorm normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release Adderall 20 mg (formulation A)
Trial: 12432966
Drug: Extended-release Adderall
RxNorm normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release Adderall 20 mg (formulation B)
Trial: 12432966
Drug: Extended-release Adderall
RxNorm normalized name: amphetamine / dextroamphetamine Extended Release Oral Capsule [Adderall]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release Adderall 20 mg (formulation C)
Trial: 12432966
Drug: SLI381 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 30 mg (intact capsule)
Trial: 12432966
Drug: SLI381 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 30 mg (sprinkled in applesauce)
Trial: 8582462
Drug: Dextropropoxyphene napsylate
RxNorm normalized name: Dextropropoxyphene napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene napsylate 100 mg
Trial: 8582462
Drug: Dextropropoxyphene napsylate
RxNorm normalized name: Dextropropoxyphene napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene napsylate 200 mg
Trial: 3407612
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Zn/d supplementation for 28 days
Trial: 11601116
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy (pool exercise therapy)
Trial: 9013436
Drug: High heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High heart rate intensity exercise (HI, N = 8) - exercised at a mean heart rate of 163 bpm for 40 to 45 minutes approximately four times weekly.
Trial: 9013436
Drug: Low heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low heart rate intensity exercise (LI, N = 7) - exercised at a mean heart rate of 132 bpm for 40 to 45 minutes approximately four times weekly.
Trial: 3928919
Drug: BCAA (valine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (valine, leucine, isoleucine) at 0.5 g/kg/day
Trial: 3928919
Drug: BCAA (valine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (valine, leucine, isoleucine) at 1.0 g/kg/day
Trial: 3928919
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg of essential and nonessential AA solution with a prevalence of BCAA
Trial: 23083787
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily (titrated to 50 mg)
Trial: 19903864
Drug: Pravastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin treatment (4 weeks)
Trial: 18817955
Drug: Naftopidil 75
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 75 mg after dinner for 6 weeks
Trial: 11429021
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1 g tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)